Drugs / Technetium99
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02997553 | Nov 2017 → Sep 2022 | anus cancer, breast carcinoma, cervical carcinoma, cutaneous melanoma +5 | Institut de Cancérologie de Lorraine | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02057393 | Jun 2014 → Jan 2016 | melanoma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02279108 Background | Nov 2014 → May 2016 | breast neoplasm | University Hospital of Saint-Etienne | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Technetium99 | “intradermal injection of 20 MBq of technetium 99 before breast surgery” NCT02279108 ↗ |
| Route | Subcutaneous | “injected subcutaneoulsy about the primary melanoma site” NCT02057393 ↗ |